GPI attended ISPOR (November 22), in Austria Center Vienna, and had the opportunity to present four research abstracts, including our research into “Suitability of value-based price forecasting in a crowded landscape: A case study in rheumatoid arthritis”.
- Value-based pricing (VBP) is utilised for health technology assessment (HTA) decision-making of new medicinal products by the National Institute for Health and Care Excellence (NICE) in England, Haute Autorité de Santé (HAS) in France and the Gemeinsamer Bundesausschuss (G-BA) in Germany.
- However, the definition of “value” and the degree to which VBP is incorporated into the HTA process varies across these markets due to the inherent differences in the evidence requirements, HTA system and payer archetypes.
- Traditional price forecasting methods incorporate price corridors benchmarked against comparators, but generally do not consider product positioning or payer-perceived value.
- Within a crowded therapeutic area with multiple comparators, determining the potential value and price of a new product from the current landscape is a challenge.
- In England, current comparator products may have similar reimbursement recommendations e.g. reimbursed with restrictions, but different prices.
- In France, current comparator products may have the same actual benefit (SMR) and improvement in actual benefit (ASMR) scores, but different prices.
- In Germany, current comparator products may have the same benefit scores, but different prices.
- Therefore, within a crowded therapeutic area, an alternative forecasting method incorporating VBP may be more appropriate.
The aim of this study was to:
- Determine the suitability of using a value-price relationship to forecast price within a crowded landscape in England, France and Germany.
Found this interesting? Download the full research here.
Share this research: